التفاصيل البيبلوغرافية
العنوان:
Molecular techniques for the personalised management of patients with chronic myeloid leukaemia
المؤلفون:
Letizia Foroni , Jane F. Apperley , Mary Alikian , Robert Peter Gale
المصدر:
Biomolecular Detection and Quantification, Vol 11, Iss C, Pp 4-20 (2017)
بيانات النشر:
Elsevier BV, 2017.
سنة النشر:
2017
مصطلحات موضوعية:
Oncology , Pathology , SCT, stem cell transplant , Review Article , Disease , Biochemistry , lcsh:Microbiology , CMR, complete molecular response/remission , ZMW, zero-mode wave-guided , 0302 clinical medicine , LSC, leukemic stem cell , EURO-SKI, European Stop Tyrosine Kinase Inhibitor Study , DESTINY, De-Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia , NTC, No Template Control , PCR, Polymerase Chain Reaction , lcsh:QH301-705.5 , ABL , RT, reverse transcription , CP, chronic phase , ALL, acute lymphoblastic leukaemia , CAP, College of American Pathology , KDa, Kilo Dalton , AP, accelerated phase , μg, microgram , RT-dPCR, reverse transcription-digital polymerase chain reaction , 030220 oncology & carcinogenesis , NGS , TKD, tyrosine kinase domain , ARQ, armored RNA Quant , IRIS, interferon and cytarabine versus STI571 , medicine.medical_specialty , Cancer therapy , IS, International Scale , cDNA, coding or complimentary DNA , RT-qPCR, reverse transcription-quantitative polymerase chain reaction , Chronic myeloid leukaemia , 03 medical and health sciences , ELN, European Leukaemia Net , STIM, stop imatinib , Molecular Biology , CML, chronic myeloid leukaemia , LPC, leukemic progenitor cells , NGS, next generation sequencing , BMT, bone marrow transplantation , Q-PCR, quantitative polymerase chain reaction , respiratory tract diseases , IC, inhibotory concentration , MMR, major molecular response/remission , SMRT, single-molecule real-time sequencing , Mbp, mega base pair , dPCR, digital polymerase chain reaction , m-bcr, minor-breakpoint cluster region , dMIQE, Minimum Information for Publication of Quantitative Digital PCR Experiments , PFS, Progression Free Survival , lcsh:QR1-502 , GUSB, glucuronidase beta gene , Kbp, Kilo Base Pairs , μ-bcr, micro-breakpoint cluster region , ABL1, Abelson murine leukaemia virus , MRD, minimal residual disease , TKI, tyrosine kinase inhibitor , DNA, deoxyribonucleic acid , Structural Biology , hemic and lymphatic diseases , CES, capillary electrophoresis sequencing , CML , μl, microliter , breakpoint cluster region , Myeloid leukemia , allo-SCT, Allogeneic Stem Cell Transplantation , LoQ, limit of quantification , mRNA, messenger RNA , medicine.anatomical_structure , MRD , emPCR, emulsion PCR , Molecular Medicine , Ph, Philadelpia , WHO, World Health Organisation , ATP, adenosine triphosphate , Bp, base pair , NCCN, National Comprehensive Cancer Network , QC, Quality Control , BC, blast crisis , LoD, limit of detection , PB, Peripheral Blood , gDNA, genomic deoxyribonucleic acid , Internal medicine , InDels, insertions and deletions , Molecular monitoring , medicine , EAC, Europe Against Cancer , nM, manomolar , business.industry , dPCR , MR, deep molecular response/remission , M-bcr, major-breakpoint cluster region , Gold standard (test) , lcsh:Biology (General) , NEQAS, National External Quality Assessement Service , BM, bone marrow , BCR, breakpoint cluster region , Bone marrow , business , 030215 immunology
الوصف:
Chronic myeloid leukemia (CML) is the paradigm for targeted cancer therapy. RT-qPCR is the gold standard for monitoring response to tyrosine kinase-inhibitor (TKI) therapy based on the reduction of blood or bone marrow BCR-ABL1. Some patients with CML and very low or undetectable levels of BCR-ABL1 transcripts can stop TKI-therapy without CML recurrence. However, about 60 percent of patients discontinuing TKI-therapy have rapid leukaemia recurrence. This has increased the need for more sensitive and specific techniques to measure residual CML cells. The clinical challenge is to determine when it is safe to stop TKI-therapy. In this review we describe and critically evaluate the current state of CML clinical management, different technologies used to monitor measurable residual disease (MRD) focus on comparingRT-qPCR and new methods entering clinical practice. We discuss advantages and disadvantages of new methods.
تدمد:
2214-7535
DOI:
10.1016/j.bdq.2017.01.001
URL الوصول:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38bbd66daeb393841cac660a98150a1a
حقوق:
OPEN
رقم الأكسشن:
edsair.doi.dedup.....38bbd66daeb393841cac660a98150a1a
قاعدة البيانات:
OpenAIRE
